PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced: MDSC-mediated T cell activation
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Tumor-infiltrating myeloid cells such as myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) form an important component of the hypoxic tumor microenvironment. Here, we investigated the influence of hypoxia on immune checkpoint receptors (programmed death [PD]-1 and CTLA-4) and their respective ligands (PD-1 ligand 1 [PD-L1], PD-L2, CD80, and CD86) on MDSCs. We demonstrate that MDSCs at the tumor site show a differential expression of PD-L1 as compared with MDSCs from peripheral lymphoid organ (spleen). Hypoxia caused a rapid, dramatic, and selective up-regulation of PD-L1 on splenic MDSCs in tumor-bearing mice. This was not limited to MDSCs, as hypoxia also significantly increased the expression of PD-L1 on macrophages, dendritic cells, and tumor cells. Furthermore, PD-L1 up-regulation under hypoxia was dependent on hypoxia-inducible factor-1α (HIF-1α) but not HIF-2α. Chromatin immunoprecipitation and luciferase reporter assay revealed direct binding of HIF-1α to a transcriptionally active hypoxia-response element (HRE) in the PD-L1 proximal promoter. Blockade of PD-L1 under hypoxia enhanced MDSC-mediated T cell activation and was accompanied by the down-regulation of MDSCs IL-6 and IL-10. Finally, neutralizing antibodies against IL-10 under hypoxia significantly abrogated the suppressive activity of MDSCs. Simultaneous blockade of PD-L1 along with inhibition of HIF-1α may thus represent a novel approach for cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![Figure 4. Blockade of PD-L1 under hypoxia down-regulates MDSC IL-6 and IL-10 and enhances T cell proliferation and function. MDSCs isolated from spleens of B16-F10 tumor-bearing mice were pretreated for 30 min on ice with 5 µg/ml control antibody (IgG) or antibody against PD-L1 (PDL1 Block) and co-cultured with splenocytes under normoxia and hypoxia for 72 h. (A and B) Effect of MDSC on proliferation of splenocytes stimulated with (A) anti-CD3/CD28 coated beads or (B) TRP-2(180–88) peptide under the indicated conditions. Cell proliferation was measured in triplicates by [3H]thymidine incorporation and expressed as counts per minute (CPM). (C and D) MDSCs were cultured with splenocytes from B16-F10 mice stimulated with anti-CD3/CD28. Intracellular IFN-γ production was evaluated by flow cytometry by gating on (C) CD3+CD8+ IFN-γ+ and (D) CD3+CD4+ IFN-γ+ populations. Statistically significant differences (indicated by asterisks) are shown (**, P < 0.005; ***, P < 0.0005). Three separate experiments (in triplicates) with the same results were performed. Error bars indicate SD. (E) SYBR-GREEN RT-qPCR was performed to evaluate the mRNA expression levels of Ldha, Car-9, Arg-1, Nos2, Ncf-1, and Cybb-1. (F) Arginase enzymatic activity measured in MDSCs under indicated conditions. (G) After 72 h of MDSC co-culture with splenocytes, supernatants were collected and assayed for nitrites. Data represents three independent experiments with SD. (H) SYBR Green RT-qPCR was performed for expression levels of IL6, IL10, Il12p70, and Tgfb1 under the indicated conditions. IL-6, IL-10, IL-12p70, and TGF-β1 cytokine production and secretion was detected by (I and J) intracellular FACS staining (isotype control is gray-shaded histogram) and (K) ELISA, respectively. Statistically significant differences (indicated by asterisks) are shown (*, P < 0.05; **, P < 0.005; ***, P < 0.0005). The experiment was performed in triplicates and repeated three times with the same results. Error bars indicate SD. (L–O) MDSCs isolated from spleens of B16-F10 tumor-bearing mice were co-cultured with splenocytes under normoxia and hypoxia for 72 h in the presence of either 10 µg/ml control antibody (IgG), anti–mouse IL-6 Functional Grade Purified neutralizing antibody (IL-6 Block) or anti–mouse IL-10 Functional Grade Purified neutralizing antibody (IL-10 Block). Effect of MDSCs on proliferation of splenocytes stimulated with (L) anti-CD3/CD28–coated beads or (M) TRP-2(180–88) peptide under the indicated conditions. Cell proliferation was measured as indicated above. MDSCs were cultured with splenocytes from B16-F10 mice stimulated with anti-CD3/CD28. Intracellular IFN-γ production was evaluated by flow cytometry by gating on (N) CD3+CD8+ IFN-γ+ and (O) CD3+CD4+ IFN-γ+ populations. Statistically significant differences (indicated by asterisks) are shown (*, P < 0.05; **, P < 0.005). Two separate experiments (in triplicates) with the same results were performed. Error bars indicate SD.](https://figures.cochat.ai/paper-figures/2ba8a156b22c410c8802e99a6f19ff08/pd-l1-is-a-novel-direct-target-of-hif-1-and-its-blockade-under-hypoxia-enhanced-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Intriguingly, HIF-1α, but not HIF-2α, directly upregulates the expression of PD-L1 in macrophages, dendritic cells and bone marrow derived macrophages (BMDMs), by binding HREs within the PD-L1 promoter (Fig. 2C) [68–70].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [68]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As seen for the other cancer axes, the HIF-α dependency of PD-L1 is tumor-type dependent, with PD-L1 expression primarily HIF-1α driven in HIF-1α-dominant cancers (such as CT26 colon carcinoma and 4T1 breast carcinoma models) and HIF-2α-driven in HIF-2α-dominant cancers (ccRCC) [81, 83].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [81]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition to regulating components of the innate immune response, the HIFs have been linked to modulation of the adaptive immune response through upregulation of both co-inhibitory (eg. PD-L1 and CTLA4) and co-stimulatory receptors (eg. 4–1BB, OX40) on activated T cells [80, 81].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [81]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent data indicate that hypoxia is also able to upregulate expression of PD-L1 in malignant cells via HIF-1α and HIF-2α (17).”
From Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy (2022) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Targeting HIF-1α in immunotherapy is a relatively new concept, for which proof of principle has been amply demonstrated by others (12, 23, 27).”
From Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues (2022) · cites this paper as [12]
Experimental — accuracy not yet measured
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · cited 1×
“A large body of preclinical and clinical data indicates that antibody blockade of immune checkpoints can significantly enhance antitumor immunity (Pardoll, 2012; West et al., 2013).”
BackgroundSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 2×
“, 2012) and its ligand, PD-L1 (Brahmer et al., 2012), was shown to result in durable tumor regression and prolonged stabilization of disease in patients with advanced cancers.”
BackgroundCoordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · cited 1×
“MDSCs are a heterogeneous group of relatively immature myeloid cells and several studies have described mechanisms of MDSCmediated immune suppression (Gabrilovich et al., 2012).”
BackgroundSelf-citationGreenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318 · cited 1×
“PD-1, a cell surface glycoprotein with a structure similar to cytotoxic T lymphocyte antigen 4 (CTLA-4), belongs to the B7 family of co-stimulatory/co-inhibitory molecules and plays a key part in immune regulation (Greenwald et al., 2005).”
BackgroundSubsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
Youn, J.-I., Nagaraj, S., Collazo, M., & Gabrilovich, D. I. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5791 · Cited by 1,645 · cited 3×
“It is important to underline that our results are in complete agreement with previous findings by Youn et al. (2008), indicating that normoxic blockade of PD-L1 did not eliminate suppressive activity of MDSCs.”
BackgroundMethodResultInfluentialBlockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314 · cited 12×
“2 I) and DCs (CD11c+; Fig.”
BackgroundResultInfluentialPD-1 and PD-1 ligands: from discovery to clinical application
Okazaki, T., & Honjo, T. (2007) · International Immunology · doi:10.1093/intimm/dxm057 · Cited by 1,310
Corzo, C. A., Condamine, T., Lu, L., Cotter, M. J., Youn, J.-I., Cheng, P., Cho, H.-I., Celis, E., Quiceno, D. G., Padhya, T., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100587 · Cited by 1,173 · cited 6×
“As shown previously by Corzo et al. (2010), we observed higher levels of Arg-1 gene expression (Fig.”
BackgroundInfluentialOxygen Sensing, Homeostasis, and Disease
Semenza, G. L. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011165 · Cited by 993 · cited 1×
“2014 Vol. 211 No. 5 781-790 www.jem.org/cgi/doi/10.1084/jem.20131916 781 Brief Definit ive Report Hypoxia is a common feature of solid tumors (Semenza, 2011).”
BackgroundInfluential
Cited by
Items 601–700 of 1,009
Lenouvel, D., González‐Moles, M. Á., Talbaoui, A., Ramos‐García, P., González‐Ruiz, L., Ruiz‐Ávila, I., & Montoya, J. A. G. (2019) · Oral Diseases · doi:10.1111/odi.13088 · Cited by 70
Liu, Y., Zhang, H., Wang, Z., Pin, W., & Gong, W. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.03.017 · Cited by 70
Meng, L., Wang, C., Lu, Y., Sheng, G., Yang, L., Wu, Z., Xu, H., Han, C., Lu, Y., & Han, F. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c00347 · Cited by 62
Guo, H., Zhang, W., Wang, L., Shao, Z., & Huang, X. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121821 · Cited by 63
Li, P., Sun, Q., Bai, S., Wang, H., & Zhao, L. (2023) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2023.5343 · Cited by 73
Tao, L., Zhou, X., Li, F.-C., Chen, Q., Meng, F., Mao, Y., Li, R., Hua, D., Zhang, H., Wang, W., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1936-0 · Cited by 62
Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens
Song, M., Chen, X., Wang, L., & Zhang, Y. (2018) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2018.02.01 · Cited by 63
Mechanisms of Resistance to NK Cell Immunotherapy
Sordo‐Bahamonde, C., Vitale, M., Lorenzo‐Herrero, S., López‐Soto, A., & Gonzalez, S. R. (2020) · Cancers · doi:10.3390/cancers12040893 · Cited by 71
Current progress in immunotherapy of hepatocellular carcinoma
Sprinzl, M. F., & Galle, P. R. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.12.009 · Cited by 65
Eckert, F., Zwirner, K., Boeke, S., Thorwarth, D., Zips, D., & Huber, S. M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00407 · Cited by 62
Bashash, D., Zandi, Z., Kashani, B., Pourbagheri‐Sigaroodi, A., Salari, S., & Ghaffari, S. H. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30575 · Cited by 65
DENR controls JAK2 translation to induce PD-L1 expression for tumor immune evasion
Chen, B., Hu, J., Hu, X., Chen, H., Bao, R., Zhou, Y., Ye, Y., Zhan, M., Cai, W., Li, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29754-y · Cited by 64
3D Tumor Spheroid and Organoid to Model Tumor Microenvironment for Cancer Immunotherapy
Zhu, Y., Kang, E., Wilson, M., Basso, T., Chen, E., Yu, Y., & Li, Y.-R. (2022) · Organoids · doi:10.3390/organoids1020012 · Cited by 66
“A blockade of PD-L1, the ligand of PD-1 immune checkpoint receptor, has been observed to reduce MDSC-mediated T cell suppression under hypoxic conditions [34].”
BackgroundShi, Z., Hu, C., Zheng, X., Sun, C., & Li, Q. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00519-1 · Cited by 75
“Under hypoxic conditions, HIF-1α upregulates PD-L1 on cancer cells and MDSCs, thereby interfering with T cell effector function [194].”
BackgroundZhu, Y., Li, M., Mu, D., Kong, L., Zhang, J., Zhao, F., Li, Z., Liu, X., Bo, C., & Yu, J. (2016) · Oncotarget · doi:10.18632/oncotarget.12213 · Cited by 66
“It might be related to the slightly worse hypoxia conditions in longer tumors, as PD-L1 is reportedly induced under hypoxia conditions [30, 31].”
BackgroundHypoxic Modulation of HLA-G Expression through the Metabolic Sensor HIF-1 in Human Cancer Cells
Garziera, M., Scarabel, L., & Toffoli, G. (2017) · Journal of Immunology Research · doi:10.1155/2017/4587520 · Cited by 60
“Binding of HIF-1 to an active HRE was assessed for a well-known cancer biomarker for cancer immunotherapy, the programmed death-ligand 1 (PD-L1), suggesting the close interaction between hypoxia and immune regulation [33].”
MethodO'Kane, G. M., Connor, A. A., & Gallinger, S. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.10.007 · Cited by 67
Gao, W.-F., Zhang, X., Yang, W., Dou, D., Zhang, H., Tang, Y., Zhong, W., Meng, J., Bai, Y., Liu, Y., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0676-z · Cited by 62
The tumor organismal environment: Role in tumor development and cancer immunotherapy
Dieterich, L. C., & Bikfalvi, A. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.021 · Cited by 68
Wang, Y., Ding, Y., Deng, Y., Zheng, Y., & Wang, S. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000609 · Cited by 61
Metabolism and immunity in breast cancer
Zhang, D., Xu, X., & Ye, Q. (2020) · Frontiers of Medicine · doi:10.1007/s11684-020-0793-6 · Cited by 63
Klemba, A., Bodnar, L., Waś, H., Brodaczewska, K. K., Wcisło, G., Szczylik, C. A., & Kiéda, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249492 · Cited by 66
“It was found in a circulating form and on key immune cells, such as dendritic cells (DCs) and macrophages [123,124].”
BackgroundZhao, Y. C., Cao, Y., Chen, Y., Wu, L., Hang, H., Jiang, C., & Zhou, X. (2021) · Immunology · doi:10.1111/imm.13384 · Cited by 67
Recent advances of nanotechnology-based tumor vessel-targeting strategies
Zhu, D., Li, Y., Zhang, Z., Xue, Z., Hua, Z., Luo, X., Zhao, T., Lu, C. C., & Liu, Y. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01190-y · Cited by 61
“Moreover, hypoxia can directly induce the upregulation of inhibitory immune checkpoints ligand (e.g., PD-L1 and cytotoxic T-lymphocyte-associated protein 4, CTLA-4) on dendritic cells (DCs), myeloid-derived suppressor cells (MDSCs), TAMs and tumor cells through HIF-1α [23].”
BackgroundInfluentialImmunometabolism in biofilm infection: lessons from cancer
Mirzaei, R., Sabokroo, N., Ahmadyousefi, Y., Motamedi, H., & Karampoor, S. (2022) · Molecular Medicine · doi:10.1186/s10020-022-00435-2 · Cited by 63
Engineering chimeric antigen receptor T cells for solid tumour therapy
Liu, L., Qu, Y., Cheng, L., Yoon, C. W., He, P., Monther, A., Guo, T., Chittle, S. J., & Wang, Y. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.1141 · Cited by 62
OXPHOS inhibitors, metabolism and targeted therapies in cancer
Cadassou, O., & Jordheim, L. P. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115531 · Cited by 59
Köstlin, N., Vogelmann, M., Spring, B., Schwarz, J., Feucht, J., Härtel, C., Orlikowsky, T. W., Poets, C. F., & Gille, C. (2017) · Immunology · doi:10.1111/imm.12751 · Cited by 68
Bian, Z., Abdelaal, A. M., Shi, L., Liang, H., Xiong, L., Kidder, K., Venkataramani, M., Culpepper, C. D., Zen, K., & Liu, Y. (2018) · European Journal of Immunology · doi:10.1002/eji.201747355 · Cited by 62
Guo, R., Li, Y., Wang, Z., Bai, H., Duan, J., Wang, S., Wang, L., & Wang, J. (2019) · Cancer Science · doi:10.1111/cas.13989 · Cited by 67
Metabolic Control of Epigenetics and Its Role in CD8+ T Cell Differentiation and Function
Yerinde, C., Siegmund, B., Glauben, R., & Weidinger, C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02718 · Cited by 65
“Similarly, due to the hypoxic environment of the tumors, HIF1α upregulates the expression of PD-1-ligand leading to inhibition of CD8 T-cell mediated cytotoxicity (76).”
BackgroundHiraoka, N., Ino, Y., Hori, S., Yamazaki–Itoh, R., Naito, C., Shimasaki, M., Esaki, M., Nara, S., Kishi, Y., Shimada, K., et al. (2020) · Cancer Science · doi:10.1111/cas.14514 · Cited by 69
Nanomedicines based on nanoscale metal-organic frameworks for cancer immunotherapy
Zhong, X., & Sun, X. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0414-6 · Cited by 61
“At the same time, the nMOFs downregulated the expression of hypoxia-inducible factor-1α, reducing the risk of drug resistance and immune escape [61].”
BackgroundModulating tumor physical microenvironment for fueling CAR-T cell therapy
Luo, Z. Y., Yao, X., Li, M., Fang, D., Fei, Y., Cheng, Z., Xu, Y., & Zhu, B. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114301 · Cited by 62
Sharma, P., & Otto, M. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.08.022 · Cited by 66
Immunological nanomaterials to combat cancer metastasis
Pan, Y., Cheng, J., Zhu, Y., Zhang, J., Fan, W., & Chen, X. S. (2024) · Chemical Society Reviews · doi:10.1039/d2cs00968d · Cited by 61
Oxygen-Enhanced MRI Is a Major Advance in Tumor Hypoxia Imaging
Dewhirst, M. W., & Birer, S. R. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2818 · Cited by 68
Heery, C. R., Madan, R. A., Stein, M. N., Stadler, W. M., DiPaola, R. S., Rauckhorst, M., Steinberg, S. M., Marté, J. L., Chen, C. C., Grenga, I., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10883 · Cited by 59
“Notably, patients receiving Sm-153-EDTMP alone, but not Sm-153-EDTMP plus vaccine, displayed an increase in several MDSC subsets, including those expressing PDL1 (PDL1 + MDSC, P = 0.016) that are reported to have a suppressive function [24].”
InfluentialPyfferoen, L., Brabants, E., Everaert, C., Cabooter, N. D., Heyns, K., Deswarte, K., Vanheerswynghels, M., Prijck, S. D., Wagemans, G., Dullaers, M., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1253655 · Cited by 64
“Moreover, PD-L1 upregulation, one of the most striking features of TIDCs in our model, was also shown to be induced by hypoxia in DCs, be it directly in a HIF-1a-dependent manner or indirectly through the action of tumor-secreted VEGF.(40,41) Remarkably, in silico prediction of dominant transcription factor motifs ind…”
BackgroundTumor oxygenation and cancer therapy—then and now
Hughes, V. S., Wiggins, J. M., & Siemann, D. W. (2018) · British Journal of Radiology · doi:10.1259/bjr.20170955 · Cited by 76
Jamieson, S. M. F., Tsai, P., Kondratyev, M. K., Budhani, P., Liu, A. J., Senzer, N. N., Chiorean, E. G., Jalal, S. I., Nemunaitis, J. J., Kee, D., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.122204 · Cited by 61
de Lara, P. T., Cecconi, V., Hiltbrunner, S., Yagita∥, H., Friess, M., Bode, B., Opitz, I., Vrugt, B., Weder, W., Stolzmann, P., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1231 · Cited by 63
“PD-L1 expression over time could be then the result of local IFNg production (35).”
BackgroundThe therapeutic landscape of hepatocellular carcinoma
Gallage, S., Beccaria, M. G., Szydlowska, M., Rahbari, M., Mohr, R. U., Tacke, F., & Heikenwälder, M. F. (2021) · Med · doi:10.1016/j.medj.2021.03.002 · Cited by 64
Huang, J., Xiao, Z., Chen, G., Li, T., Peng, Y., & Shuai, X. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101390 · Cited by 58
Ghosh, R., Samanta, P., Sarkar, R., Biswas, S., Saha, P., Hajra, S., & Bhowmik, A. (2022) · Molecules · doi:10.3390/molecules27165192 · Cited by 248
Immune checkpoint blockade in pancreatic cancer: Trudging through the immune desert
Li, X., Gulati, M., Larson, A. C., Solheim, J. C., Jain, M., Kumar, S., & Batra, S. K. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.08.009 · Cited by 58
Faisal, S. M., Comba, A., Varela, M. L., Argento, A. E., Brumley, E. K., Abel, C. C., Castro, M. G., & Lowenstein, P. R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1005069 · Cited by 62
Li, Y., Xiang, S., Pan, W., Wang, J., Zhan, H., & Liu, S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1166860 · Cited by 72
Lepone, L. M., Donahue, R. N., Grenga, I., Metenou, S., Richards, J., Heery, C. R., Madan, R. A., Gulley, J. L., & Schlom, J. (2016) · Journal of Circulating Biomarkers · doi:10.5772/62322 · Cited by 58
“0088, Figure 5E), a marker that has been implicated in suppressive function [18].”
BackgroundImmunomodulatory aspects in the progression and treatment of oral malignancy
Kondoh, N., Mizuno‐Kamiya, M., Umemura, N., Takayama, E., Kawaki, H., Mitsudo, K., Muramatsu, Y., & Sumitomo, S. (2019) · Japanese Dental Science Review · doi:10.1016/j.jdsr.2019.09.001 · Cited by 61
Targeting PD-1 or PD-L1 in Metastatic Kidney Cancer: Combination Therapy in the First-Line Setting
Aggen, D. H., Drake, C. G., & Rini, B. I. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3323 · Cited by 60
“In addition, accumulation of HIF1a alters PD-L1 expression on immune cell subsets (71).”
BackgroundShima, T., Shimoda, M., Shigenobu, T., Ohtsuka, T., Nishimura, T., Emoto, K., Hayashi, Y., Iwasaki, T., Abe, T., Asamura, H., et al. (2019) · Cancer Science · doi:10.1111/cas.14272 · Cited by 63
The tumor microenvironment shapes the molecular characteristics of exhausted CD8+ T cells
Cheng, H., Ma, K., Zhang, L., & Li, G. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.02.013 · Cited by 65
PD-L1 regulation revisited: impact on immunotherapeutic strategies
Lucibello, G., Mograbi, B., Milano, G. A., Hofman, P. M., & Brest, P. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.06.005 · Cited by 57
Hypoxia signaling in hepatocellular carcinoma: Challenges and therapeutic opportunities
Sin, Q. S., Mohan, C. D., Goh, R. M., You, M., Nayak, S. C., Chen, L., Sethi, G., Rangappa, K. S., & Wang, L. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10071-1 · Cited by 62
“Moreover, it is known that MDSCs and HIF-1α can alter the expression of immune checkpoint receptor-ligand PD-L1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) [105].”
BackgroundHao, B., Dong, H., Xiong, R., Song, C., Xu, C., Li, N., & Geng, Q. (2024) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2024.108183 · Cited by 60
Li, J., Liang, Y.-B., Wang, Q., Luo, W.-L., Chen, X., Lakang, Y., Yang, Z.-S., Zuo, J.-X., Li, Y.-K., Li, Z., et al. (2025) · Liver Cancer · doi:10.1159/000549355 · Cited by 84
“Mecha-nistically, sorafenib induces a hypoxic condition in HCC, activating the HIF-1α pathway to upregulate PD-L1 expression in HCC cells, thereby providing targets for anti-PD-L1 to exert antitumor immunity [94].”
ILT4 functions as a potential checkpoint molecule for tumor immunotherapy
Gao, A., Sun, Y., & Peng, G. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.04.001 · Cited by 61
Metabolic regulation of T cells in the tumor microenvironment by nutrient availability and diet
Zhao, S., Peralta, R. M., Avina-Ochoa, N., Delgoffe, G. M., & Kaech, S. M. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101485 · Cited by 67
Hypoxia-Regulated Tumor-Derived Exosomes and Tumor Progression: A Focus on Immune Evasion
Shao, X., Hua, S., Feng, T., Ocansey, D. K. W., & Yin, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911789 · Cited by 69
“Under hypoxia, MDSCs are enhanced to express IL-10 and IL-6 to promote the suppressive activity of MDSCs [196].”
BackgroundROS regulation in gliomas: implications for treatment strategies
Yang, Y.-C., Zhu, Y., Sun, S.-J., Zhao, C.-J., Bai, Y., Wang, J., & Ma, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1259797 · Cited by 64
The emerging role of myeloid-derived suppressor cells in radiotherapy
Kang, C., Jeong, S., Song, S. Y., & Choi, E. K. (2020) · Radiation Oncology Journal · doi:10.3857/roj.2019.00640 · Cited by 56
“The binding of PD-L1 to PD-1 receptor on T cells leads to the anergic state in T cells [42].”
BackgroundChang, W. H., & Lai, A. G. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.05.011 · Cited by 55
Metabolism of Innate Immune Cells in Cancer
Talty, R., & Olino, K. L. (2021) · Cancers · doi:10.3390/cancers13040904 · Cited by 60
“Blocking fatty acid oxidation with etomoxir prevented the tolerogenic functions of MDSCs, resulted in T cell-dependent inhibition of tumor growth, and enhanced the antitumor effect of low-dose chemotherapy and adoptive T cell therapy.”
BackgroundInfluentialWang, J., Yu, Z., Wang, J., Shen, Y., Qiu, J., & Zhuang, Z. (2020) · Cancer Medicine · doi:10.1002/cam4.3544 · Cited by 54
Immunotherapeutic approaches for hepatocellular carcinoma
Longo, V., Gnoni, A., Gardini, A. C., Pisconti, S., Licchetta, A., Scartozzi, M., Memeo, R., Palmieri, V. O., Aprile, G., Santini, D., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15406 · Cited by 59
“At the same time, excessive pruning of tumor vasculature over time could aggravate hypoxia in the tumor microenviroment, resulting in high hypoxia-inducible factor-1α (HIF)-1α levels, which enhances immune checkpoint molecules expression such as PD-L1 in MDSCs and macrophages [30].”
BackgroundMetabolic reprograming of MDSCs within tumor microenvironment and targeting for cancer immunotherapy
Li, Q., & Xiang, M. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00776-4 · Cited by 59
The importance of hypoxia in radiotherapy for the immune response, metastatic potential and FLASH-RT
Moon, E. J., Petersson, K., & Olcina, M. M. (2021) · International Journal of Radiation Biology · doi:10.1080/09553002.2021.1988178 · Cited by 63
“HIF-1a also upregulates immune checkpoint factors such as PD-L1 on MDSCs, macrophages, dendritic cells, and tumor cells (Noman et al. 2014).”
BackgroundZhou, Z., Wang, H., Li, J., Jiang, X., Li, Z., & Shen, J. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.127911 · Cited by 61
Shigeta, K., Kosaka, T., Kitano, S., Yasumizu, Y., Miyazaki, Y. J., Mizuno, R., Shinojima, T., Kikuchi, E., Miyajima, A., Tanoguchi, H., et al. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-016-5354-5 · Cited by 59
“A noteworthy report demonstrated that TAMs inhibited T-cell activation via the interaction between programmed cell death 1 (PD-1) and its ligand PD-L1, leading to suppression of antitumor activity.(21,22) It was explained that the increased TAM accumulation blocks this PD-1/PD-L1 interaction and promotes immunosuppres…”
Yang, Q., Li, X., Chen, H., Cao, Y., Xiao, Q., He, Y., Wei, J., & Zhou, J. (2017) · Oncogene · doi:10.1038/onc.2016.448 · Cited by 59
Correlation of tumor-related immunity with 18F-FDG-PET in pulmonary squamous-cell carcinoma
Kasahara, N., Kaira, K., Bao, P., Higuchi, T., Arisaka, Y., Erkhem‐Ochir, B., Sunaga, N., Ohtaki, Y., Yajima, T., Kosaka, T., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.03.001 · Cited by 55
Hypoxic Signalling in Tumour Stroma
Laitala, A., & Erler, J. T. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00189 · Cited by 58
“Tumor-infiltrating MDSCs, as well as macrophages and tumor cells, were shown to have increased levels of the cell surface protein PD-L1, which was shown to be an HIF-1α target and upregulated by hypoxia.”
BackgroundInfluentialOvercoming immunotherapeutic resistance by targeting the cancer inflammation cycle
Wattenberg, M. M., & Beatty, G. L. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.01.002 · Cited by 59
Beyond bystanders: Myeloid cells in chronic lymphocytic leukemia
Hanna, B. S., Öztürk, S., & Seiffert, M. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.11.014 · Cited by 56
Pratt, H. G., Steinberger, K. J., Mihalik, N. E., Ott, S., Whalley, T., Szomolay, B., Boone, B. A., & Eubank, T. D. (2021) · Cancers · doi:10.3390/cancers14010194 · Cited by 60
“Further, PMN-MDSCs, through HIF-1α signaling, can upregulate PD-L1 [191].”
InfluentialImmune cellular components and signaling pathways in the tumor microenvironment
Yenyuwadee, S., Aliazis, K., Wang, Q., Christofides, A., Shah, R., Patsoukis, N., & Boussiotis, V. A. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.08.004 · Cited by 55
Gao, D., Fang, L., Liu, C., Yang, M., Yu, X., Wang, L., Zhang, W., Sun, C., & Zhuang, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115622 · Cited by 61
Radiation Therapy and Myeloid-Derived Suppressor Cells: Breaking Down Their Cancerous Partnership
Bergerud, K. B., Berkseth, M., Pardoll, D. M., Ganguly, S., Kleinberg, L. R., Lawrence, J., Odde, D. J., Largaespada, D. A., Terezakis, S. A., & Sloan, L. (2023) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2023.11.050 · Cited by 66
“117 In tumor-bearing mice, hypoxia prompts the rapid upregulation of PD-L1 on MDSCs resulting from the direct binding of HIF-1 α to the hypoxia-response element in the PD-L1 proximal promoter.”
BackgroundWang, Q., Yu, M., & Zhang, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1440830 · Cited by 68
The innate immune architecture of lung tumors and its implication in disease progression
Milette, S., Fiset, P., Walsh, L. A., Spicer, J. D., & Quail, D. F. (2019) · The Journal of Pathology · doi:10.1002/path.5241 · Cited by 58
“In mouse models of LLC, HIF-1α was also shown to directly up-regulate the expression of the co-inhibitory receptor programmed death ligand-1 (PD-L1) in Gr1+ myeloid cells, which led to a progressive loss of T cell function [149].”
BackgroundAntitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemia
Hayashi, Y., Goyama, S., Liu, X., Tamura, M., Asada, S., Tanaka, Y., Fukuyama, T., Wunderlich, M., O'Brien, E. J., Mizukawa, B. E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12555-1 · Cited by 57
Signaling in and out: long-noncoding RNAs in tumor hypoxia
Kuo, T.-C., Kung, H.-J., & Shih, J.-W. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-020-00654-x · Cited by 56
Interferon‑γ induced PD‑L1 expression and soluble PD‑L1 production in gastric cancer
Imai, Y., Chiba, T., Kondo, T., Kanzaki, H., Kanayama, K., Ao, J., Kojima, R., Kusakabe, Y., Nakamura, M. R., Saito, T., et al. (2020) · Oncology Letters · doi:10.3892/ol.2020.11757 · Cited by 57
Giatromanolaki, A. N., Harris, A. L., Banham, A. H., Contrafouris, C., & Koukourakis, M. I. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0756-3 · Cited by 54
Li, J., Qiao, H., Wu, F., Sun, S., Feng, C., Li, C., Yan, W., Lv, W., Wu, H., Liu, M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.998140 · Cited by 62
Immune checkpoint inhibitors in bone metastasis: Clinical challenges, toxicities, and mechanisms
Joseph, G. J., Johnson, D. B., & Johnson, R. W. (2023) · Journal of bone oncology · doi:10.1016/j.jbo.2023.100505 · Cited by 58
“Pre-clinical studies suggest the importance of multiple immune cell subsets (e.g., MDSCs, CD8 + T cells), PD-1/PD-L1 expression in the bone microenvironment, and the hypoxic bone and tumor microenvironments in tumor-induced bone disease.”
BackgroundInfluentialImmune checkpoint blockade: Releasing the brake towards hematological malignancies
Xia, Y., Medeiros, L. J., & Young, K. H. (2015) · Blood Reviews · doi:10.1016/j.blre.2015.11.003 · Cited by 56
“MDSCs at tumor sites show elevated expression of PD-L1 [90].”
BackgroundA New VISTA on combination therapy for negative checkpoint regulator blockade
Deng, J., Mercier, I. L., Kuta, A., & Noelle, R. J. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0190-5 · Cited by 57
“cell oncogenes [48–53] or by other mediators highly expressed within the tumor microenvironment (TME) such as tumor hypoxia [30], TLR-mediated signaling pathways [54], and IFNγ [55].”
BackgroundTuccitto, A., Shahaj, E., Vergani, E., Ferro, S., Huber, V., Rodolfo, M., Castelli, C., Rivoltini, L., & Vallacchi, V. (2018) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-018-2477-z · Cited by 55
Köstlin‐Gille, N., Dietz, S., Schwarz, J., Spring, B., Pauluschke‐Fröhlich, J., Poets, C. F., & Gille, C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00161 · Cited by 62
Radiotherapy in Combination With Cytokine Treatment
Palata, O., Podzimkova, N., Nedvedova, E., Umprecht, A., Sadilkova, L. K., Jelinkova, L. P., Špíšek, R., & Adkins, I. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00367 · Cited by 55
PD-L1/PD-1 axis as a potent therapeutic target in breast cancer
Bastaki, S., Irandoust, M., Ahmadi, A., Hojjat‐Farsangi, M., Ambrose, P., Hallaj, S., Edalati, M., Ghalamfarsa, G., Azizi, G., Yousefi, M., et al. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117437 · Cited by 52
Wen, Q., Yang, Z., Zhu, J., Qiu, Q., Dai, H., Feng, A., & Xing, L. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s261068 · Cited by 53
Yang, Y., Zhao, T., Chen, Q., Li, Y., Xiao, Z., Xiang, Y., Wang, B., Qiu, Y., Tu, S., Jiang, Y., et al. (2022) · Advanced Science · doi:10.1002/advs.202202797 · Cited by 59
Ran, X., & Yang, K. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s140687 · Cited by 51
“31 The second mechanism is amplification of genes coding PD-L1 ( 9p24.”
The regulation of immune checkpoints by the hypoxic tumor microenvironment
Hu, M., Li, Y., Lu, Y., Wang, M., Li, Y., Wang, C., Li, Q., & Zhao, H. (2021) · PeerJ · doi:10.7717/peerj.11306 · Cited by 51
Karimi, S., Mansouri, S., Mamatjan, Y., Liu, J., Nassiri, F., Suppiah, S., Singh, O., Aldape, K., & Zadeh, G. M. (2020) · Scientific Reports · doi:10.1038/s41598-020-70514-z · Cited by 51
Park, J. A., Wang, L., & Cheung, N. V. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01156-5 · Cited by 52
Khouzam, R. A., Janji, B., Thiery, J., Zaarour, R. F., Chamseddine, A. N., Mayr, H., Savagner, P., Kiéda, C., Gad, S., Buart, S., et al. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.11.008 · Cited by 58
Self-citation
Metadata
- Authors
- Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S.
- Affiliations
- Inserm (FR)
- Istituto Oncologico Veneto (IT)
- Centre de Recherche Public de la Santé (LU)
- Institut Gustave Roussy (FR)
- University of Verona (IT)
- Unité Institut National de la Santé et de la Recherche Médicale U753, Institut de Cancérologie Gustave Roussy, 94805 Villejuif, France 1
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2014-04-28
- Volume
- 211
- Issue
- 5
- Pages
- 781-790
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC4010891
- OpenAlex
- W2149360266
- Semantic Scholar
- dad078dcb463c50f1571acb3306b01954a153c29
- Cited by
- 2,166
- References
- 24
- Citations by year
- 2026: 171 · 2025: 187 · 2024: 208 · 2023: 219 · 2022: 239 · 2021: 331 · 2020: 224 · 2019: 147 · 2018: 139 · 2017: 120 · 2016: 101 · 2015: 61 · 2014: 18
- FWCI
- 48.31
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc-sa
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- PD-L1, HIF-1α, hypoxia, myeloid-derived suppressor cells, tumor microenvironment, immune checkpoint blockade, T cell activation, hypoxia response element, IL-10, interleukin-6, tumor-associated macrophages, cancer immunotherapy, CTLA-4, PD-1 ligands
- MeSH terms
- Animals, Diamines, Enzyme-Linked Immunosorbent Assay, Female, Flow Cytometry, Gene Expression Regulation, Luciferases, Lymphocyte Activation, Mice, Inbred C57BL, Organic Chemicals, Quinolines, T-Lymphocytes, Cell Hypoxia, Myeloid Cells, RNA Interference, Chromatin Immunoprecipitation, Mice, Hypoxia-Inducible Factor 1, alpha Subunit, Benzothiazoles, Tumor Microenvironment, Real-Time Polymerase Chain Reaction, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.